Gilead Sciences (GILD) Misses Q4 EPS by 37c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results
February 4, 2020 4:01 PM EST- Fourth Quarter Product Sales of $5.8 billion -
- Full Year 2019 Product Sales of $22.1 billion -
- Full Year 2019 Diluted EPS of $4.22 per share -
- Full Year 2019 Non-GAAP Diluted EPS of $6.63 per share -
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2019. Total revenues for the fourth quarter of 2019 were $5.9 billion compared to... More
